Current status of hematopoietic stem cell transplant in chronic myeloid leukemia

被引：7

作者：

Gupta, Alok ^{[1
]}

Khattry, Navin ^{[1
]}

机构：

[1] Tata Mem Hosp, ACTREC, Dept Med Oncol, Bone Marrow Transplant Unit, Mumbai, Maharashtra, India

来源：

INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY | 2014年 / 35卷 / 03期

关键词：

Chronic myeloid leukemia; hematopoietic stem cell transplant; posttransplant relapse;

D O I：

10.4103/0971-5851.142036

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Indications for hematopoietic stem cell transplant (HSCT) in chronic myeloid leukemia (CML) have changed over time. This change has largely been influenced by the advent of tyrosine kinase inhibitors, increased understanding of the mechanisms underlying disease phase progression as well as drug resistance, refinement of transplant techniques and exploitation of graft versus leukemia effect in this disease. Here, we have discussed the status of HSCT in CML in the present era with regards to the current indications, factors determining outcome and management strategies for posttransplant relapse.

引用

页码：207 / 210

页数：4

共 36 条

[11]

Enright H, 1996, BONE MARROW TRANSPL, V17, P537

[12]

GOLDMAN JM, 1993, BLOOD, V82, P2235

[13] Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation [J].

Gratwohl, A ;

Hermans, J ;

Goldman, JM ;

Arcese, W ;

Carreras, E ;

Devergie, A ;

Frassoni, F ;

Gahrton, G ;

Kolb, H ;

Niederwieser, D ;

Ruutu, T ;

Vernant, JP ;

de Witte, T ;

Apperley, J .

LANCET, 1998, 352 (9134) :1087-1092

[14] Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia [J].

Hansen, JA ;

Gooley, TA ;

Martin, PJ ;

Appelbaum, F ;

Chauncey, TR ;

Clift, RA ;

Petersdorf, EW ;

Radich, J ;

Sanders, JE ;

Storb, RF ;

Sullivan, KM ;

Anasetti, C .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (14) :962-968

[15] Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia [J].

Hochhaus, A. ;

O'Brien, S. G. ;

Guilhot, F. ;

Druker, B. J. ;

Branford, S. ;

Foroni, L. ;

Goldman, J. M. ;

Mueller, M. C. ;

Radich, J. P. ;

Rudoltz, M. ;

Mone, M. ;

Gathmann, I. ;

Hughes, T. P. ;

Larson, R. A. .

LEUKEMIA, 2009, 23 (06) :1054-1061

[16] Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia - Comparison with historic experience [J].

Kantarjian, H ;

Talpaz, M ;

O'Brien, S ;

Giles, F ;

Faderl, S ;

Verstovsek, S ;

Garcia-Manero, G ;

Shan, JQ ;

Rios, MB ;

Champlin, R ;

de Lima, M ;

Cortes, J .

CANCER, 2005, 103 (10) :2099-2108

[17] Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure [J].

Kantarjian, Hagop ;

O'Brien, Susan ;

Talpaz, Moshe ;

Borthakur, Gautarn ;

Ravandi, Farhad ;

Faderl, Stefan ;

Verstovsek, Srdan ;

Rios, Mary Beth ;

Shan, Jianqin ;

Giles, Francis ;

Cortes, Jorge .

CANCER, 2007, 109 (08) :1556-1560

[18] Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia [J].

Kantarjian, HM ;

O'Brien, S ;

Cortes, JE ;

Giralt, SA ;

Rios, MB ;

Shan, JQ ;

Giles, FJ ;

Thomas, DA ;

Faderl, S ;

De Lima, M ;

Garcia-Manero, G ;

Champlin, R ;

Arlinghaus, R ;

Talpaz, M .

BLOOD, 2002, 100 (05) :1590-1595

[19] Graft-versus-leukemia reactions in allogeneic chimeras [J].

Kolb, HJ ;

Schmid, C ;

Barrett, AJ ;

Schendel, DJ .

BLOOD, 2004, 103 (03) :767-776

[20] GRAFT-VERSUS-LEUKEMIA EFFECT OF DONOR LYMPHOCYTE TRANSFUSIONS IN MARROW GRAFTED PATIENTS [J].

KOLB, HJ ;

SCHATTENBERG, A ;

GOLDMAN, JM ;

HERTENSTEIN, B ;

JACOBSEN, N ;

ARCESE, W ;

LJUNGMAN, P ;

FERRANT, A ;

VERDONCK, L ;

NIEDERWIESER, D ;

VANRHEE, F ;

MITTERMUELLER, J ;

DEWITTE, T ;

HOLLER, E ;

ANSARI, H .

BLOOD, 1995, 86 (05) :2041-2050

← 1 2 3 4 →